China-based Ascletis Pharma Inc. (HKG: 1672) has announced receiving the Notice of Issuance from the United States Patent and Trademark Office (USPTO) for the patent application of oral viral polymerase inhibitor ASC10 and its derivatives, and their uses to treat multiple virus infections including SARS-CoV-2, monkeypox virus, and respiratory syncytial virus (RSV). The issue date of the patent will be January 3, 2023, by the USPTO and the patent title is Nucleoside Derivatives and Methods of Use Thereof (US patent number: 11,541,071).
Drug Profile and Development
ASC10 is an orally bioavailable double prodrug that has a new and differentiated chemical structure from the single prodrug molnupiravir. After oral administration, both ASC10 and molnupiravir are rapidly and completely converted in vivo into the same active drug ASC10-A, also known as β-D-N4-hydroxycytidine (NHC) or EIDD-1931. ASC10 was discovered and developed in-house.
Future Prospects and Strategic Implications
The issuance of the USPTO patent for ASC10 positions Ascletis Pharma to further advance its innovative antiviral therapy. By securing intellectual property protection for ASC10 and its derivatives, Ascletis aims to address significant unmet medical needs in the treatment of multiple virus infections, contributing to the global effort to combat infectious diseases.-Fineline Info & Tech
